Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1039 participants.
Also called NCT01093807
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,039 participants
- Sponsor
- RECORDATI GROUP
- Registry
-
NCT01093807
-
- Other papers using this trial's data
- Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT01093807. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension
- Acronym
- FELT
- Condition
- Essential Hypertension
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Lercanidipine
- Intervention (Drug)
- Lercanidipine
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- Enalapril
- Intervention (Drug)
- Lercanidipine + Enalapril
- Intervention (Drug)
- Lercanidipine + Enalapril
- Intervention (Drug)
- Lercanidipine + Enalapril
- Intervention (Drug)
- Lercanidipine + Enalapril
- Lead sponsor
- RECORDATI GROUP
Record details
- Record id
cardio:ct-nct01093807- Content hash
a395a940c5a4f41b03aae39b6fcdf5f29f414032261ba8339b07813f913c2378